Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 262


A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.

Spohn G, Jennings GT, Martina BE, Keller I, Beck M, Pumpens P, Osterhaus AD, Bachmann MF.

Virol J. 2010 Jul 6;7:146. doi: 10.1186/1743-422X-7-146.


A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.

Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, Bürki K, Liebert UG, Ulbert S.

Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116.


Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.

Martina BE, Koraka P, van den Doel P, van Amerongen G, Rimmelzwaan GF, Osterhaus AD.

Vaccine. 2008 Jan 10;26(2):153-7.


Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.

Gershoni-Yahalom O, Landes S, Kleiman-Shoval S, Ben-Nathan D, Kam M, Lachmi BE, Khinich Y, Simanov M, Samina I, Eitan A, Cohen IR, Rager-Zisman B, Porgador A.

Immunology. 2010 Aug;130(4):527-35. doi: 10.1111/j.1365-2567.2010.03251.x.


A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.

Martina BE, van den Doel P, Koraka P, van Amerongen G, Spohn G, Haagmans BL, Provacia LB, Osterhaus AD, Rimmelzwaan GF.

PLoS One. 2011 Apr 26;6(4):e18995. doi: 10.1371/journal.pone.0018995.


Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, Ross TM.

Virol J. 2010 May 12;7:95. doi: 10.1186/1743-422X-7-95.


A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.

McDonald WF, Huleatt JW, Foellmer HG, Hewitt D, Tang J, Desai P, Price A, Jacobs A, Takahashi VN, Huang Y, Nakaar V, Alexopoulou L, Fikrig E, Powell TJ.

J Infect Dis. 2007 Jun 1;195(11):1607-17.


Recombinant West Nile virus envelope protein E and domain III expressed in insect larvae protects mice against West Nile disease.

Alonso-Padilla J, de Oya NJ, Blázquez AB, Escribano-Romero E, Escribano JM, Saiz JC.

Vaccine. 2011 Feb 17;29(9):1830-5. doi: 10.1016/j.vaccine.2010.12.081.


Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.

Desprès P, Combredet C, Frenkiel MP, Lorin C, Brahic M, Tangy F.

J Infect Dis. 2005 Jan 15;191(2):207-14.


Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge.

De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lorincz O, Sanders NN.

PLoS One. 2014 Feb 4;9(2):e87837. doi: 10.1371/journal.pone.0087837. Erratum in: PLoS One. 2014;9(2):e91631.


Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.

Tinker JK, Yan J, Knippel RJ, Panayiotou P, Cornell KA.

Toxins (Basel). 2014 Apr 22;6(4):1397-418. doi: 10.3390/toxins6041397.


Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.

Magnusson SE, Karlsson KH, Reimer JM, Corbach-Söhle S, Patel S, Richner JM, Nowotny N, Barzon L, Bengtsson KL, Ulbert S, Diamond MS, Stertman L.

Vaccine. 2014 Feb 7;32(7):800-8. doi: 10.1016/j.vaccine.2013.12.030.


A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.

Hughes HR, Crill WD, Davis BS, Chang GJ.

Virology. 2012 Mar 15;424(2):129-37. doi: 10.1016/j.virol.2011.12.012.


A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Bonafé N, Rininger JA, Chubet RG, Foellmer HG, Fader S, Anderson JF, Bushmich SL, Anthony K, Ledizet M, Fikrig E, Koski RA, Kaplan P.

Vaccine. 2009 Jan 7;27(2):213-22. doi: 10.1016/j.vaccine.2008.10.046.


Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate.

Ohtaki N, Takahashi H, Kaneko K, Gomi Y, Ishikawa T, Higashi Y, Kurata T, Sata T, Kojima A.

Vaccine. 2010 Sep 14;28(40):6588-96. doi: 10.1016/j.vaccine.2010.07.055.


Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.

Minke JM, Siger L, Cupillard L, Powers B, Bakonyi T, Boyum S, Nowotny N, Bowen R.

Vaccine. 2011 Jun 20;29(28):4608-12. doi: 10.1016/j.vaccine.2011.04.058.


Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII.

Ramanathan MP, Kutzler MA, Kuo YC, Yan J, Liu H, Shah V, Bawa A, Selling B, Sardesai NY, Kim JJ, Weiner DB.

Vaccine. 2009 Jul 9;27(32):4370-80. doi: 10.1016/j.vaccine.2009.01.137.


Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.

Li XF, Zhao W, Lin F, Ye Q, Wang HJ, Yang D, Li SH, Zhao H, Xu YP, Ma J, Deng YQ, Zhang Y, Qin ED, Qin CF.

J Gen Virol. 2013 Dec;94(Pt 12):2700-9. doi: 10.1099/vir.0.059436-0.

Items per page

Supplemental Content

Support Center